Drugs / GSK706769
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00975936 | Sep → Nov 2009 | autoimmune disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00723775 | Jul → Nov 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00711386 | May → Sep 2008 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00539201 | Sep 2007 → Feb 2008 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00979771 | Feb 2010 → Apr 2011 | rheumatoid arthritis | GlaxoSmithKline | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK706769 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00979771 ↗ |
| Route | Oral | “new oral formulation of GSK706769” NCT00723775 ↗ |